109 related articles for article (PubMed ID: 11920261)
1. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Bosly A; Lepage E; Coiffier B; Fillet G; Herbrecht R; Divine M; Dupriez B; Nouvel C; Deconninck E; Tilly H; Bordessoule D; Gaulard P; Gisselbrecht C;
Hematol J; 2001; 2(4):279-85. PubMed ID: 11920261
[TBL] [Abstract][Full Text] [Related]
2. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP
Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387
[TBL] [Abstract][Full Text] [Related]
3. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Tilly H; Lepage E; Coiffier B; Blanc M; Herbrecht R; Bosly A; Attal M; Fillet G; Guettier C; Molina TJ; Gisselbrecht C; Reyes F;
Blood; 2003 Dec; 102(13):4284-9. PubMed ID: 12920037
[TBL] [Abstract][Full Text] [Related]
4. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma.
Martelli M; Guglielmi C; Coluzzi S; Avvisati G; Amadori S; Giovannini M; Torromeo C; Mandelli F
J Clin Oncol; 1993 Dec; 11(12):2362-9. PubMed ID: 7504091
[TBL] [Abstract][Full Text] [Related]
5. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
[TBL] [Abstract][Full Text] [Related]
6. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
[TBL] [Abstract][Full Text] [Related]
7. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
8. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B
J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
11. VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Herbrecht R; Garcia JJ; Bergerat JP; Dufour P; Duclos B; Oberling F
Cancer Chemother Pharmacol; 1989; 24(5):338-9. PubMed ID: 2474382
[TBL] [Abstract][Full Text] [Related]
12. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
[TBL] [Abstract][Full Text] [Related]
13. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
14. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
15. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
16. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.
Herbrecht R; Ortiz S; Damonte JC; Liu KL; Maloisel F; Dufour P; Bergerat JP; Oberling F
Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
18. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Haioun C; Lepage E; Gisselbrecht C; Salles G; Coiffier B; Brice P; Bosly A; Morel P; Nouvel C; Tilly H; Lederlin P; Sebban C; Brière J; Gaulard P; Reyes F
J Clin Oncol; 2000 Aug; 18(16):3025-30. PubMed ID: 10944137
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
Morel P; Munck JN; Coiffier B; Gisselbrecht C; Ranta D; Bosly A; Tilly H; Quesnel B; Thyss A; Mounier N; Brière J; Molina T; Reyes F;
Leuk Lymphoma; 2010 Sep; 51(9):1668-77. PubMed ID: 20807094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
